Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

PHASE3CompletedINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

May 3, 2022

Study Completion Date

May 17, 2022

Conditions
Acute Myocardial Infarction
Interventions
DRUG

Empagliflozin 10 mg

The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.

DRUG

Placebo Oral Tablet

The subject will receive Placebo orally once daily for 26 weeks.

Trial Locations (11)

1030

Krankenanstalt Rudolfstiftung, Vienna

1090

Allgemeines Krankenhaus Vienna, Vienna

3100

Universitätsklinikum St. Pölten, Sankt Pölten

4021

Kepler Universitätsklinikum Linz, Linz

5020

Uniklinikum Salzburg, Salzburg

5620

Kardinal schwarzenberg Klinikum Schwarzach, Schwarzach im Pongau

6800

VIVIT Institut am akademischen Lehrkrankenhaus Feldkirch, Feldkirch

7000

Barmherzige Brüder Eisenstadt, Eisenstadt

8020

Landeskrankenhaus Graz II Standort West, Graz

8036

Medical University of Graz, Graz

9020

Klinikum Klagenfurt am Wörthersee, Klagenfurt

All Listed Sponsors
collaborator

United Arab Emirates University

OTHER

collaborator

Medical University of Vienna

OTHER

collaborator

Landeskrankenhaus Feldkirch

OTHER

collaborator

Paracelsus Medical University

OTHER

collaborator

Hospital Rudolfstiftung

OTHER

collaborator

Klinikum Klagenfurt am Wörthersee

OTHER

collaborator

Barmherzige Brüder Eisenstadt

OTHER

collaborator

Cardinal Schwarzenberg Hospital

OTHER

collaborator

Johannes Kepler University of Linz

OTHER

collaborator

Landesklinikum Sankt Polten

OTHER

collaborator

Landeskrankenhaus II Graz West

OTHER

lead

Medical University of Graz

OTHER

NCT03087773 - Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction | Biotech Hunter | Biotech Hunter